Poewe, Werner http://orcid.org/0000-0003-4367-0971
Stankovic, Iva
Halliday, Glenda http://orcid.org/0000-0003-0422-8398
Meissner, Wassilios G. http://orcid.org/0000-0003-2172-7527
Wenning, Gregor K.
Pellecchia, Maria Teresa
Seppi, Klaus http://orcid.org/0000-0001-6503-1455
Palma, Jose-Alberto http://orcid.org/0000-0002-1345-6774
Kaufmann, Horacio http://orcid.org/0000-0002-1851-9981
Article History
Accepted: 1 July 2022
First Online: 25 August 2022
Competing interests
: W.P. reports consultancy and lecture fees from Alterity, AbbVie, Affiris, AstraZeneca, BIAL, Biogen, Britannia, Lilly, Lundbeck, Neuroderm, Neurocrine, Denali Pharmaceuticals, Roche, Takeda, Teva, UCB and Zambon, as well as royalties from Thieme, Wiley Blackwell, Oxford University Press and Cambridge University Press, and grant support from the Michael J. Fox Foundation (MJFF) and the EU FP7 & Horizon 2020 programmes. G.H. reports consultancy for the NHMRC, royalties from Academic Press, Elsevier and Oxford University Press, and research grants from NHMRC, NHMRC-EU Joint Programme on Neurodegenerative Disease, NHMRC-NIHR Collaborative Research, NIH (RO1), Aligning Science Across Parkinson’s (ASAP), MJFF, Shake-it-up Australia, and the University of Sydney. W.G.M. has received fees for editorial activities with Elsevier, has served as adviser for Lundbeck, Biohaven, Roche, Alterity, Servier, Inhibikase and Takeda, and has received teaching honoraria from UCB. G.K.W. reports consultancy and lecture fees from Biogen, Biohaven, Inhibikase, Lundbeck, Ono, Takeda, and Theravance, and research grants from the FWF Austrian Science Fund, the Austrian National Bank, the US MSA Coalition, Parkinson Fonds Austria, and International Parkinson and Movement Disorder Society outside the submitted work. M.T.P. reports consultancy and lecture fees from Zambon, Orion, Teva and Theravance. K.S. reports personal fees from Teva, UCB, Lundbeck, AOP Orphan Pharmaceuticals AG, Roche, Grünenthal, Stada, Licher Pharma, Biogen, BIAL and Abbvie, honoraria from the International Parkinson and Movement Disorders Society, research grants from FWF Austrian Science Fund, MJFF, and AOP Orphan Pharmaceuticals AG. J.-A.P. reports research funding from the National Institutes of Health (NIH, R01, U54, U01), MJFF, MSA Coalition, Familial Dysautonomia Foundation, and the FDA. He has served as advisory board member for Takeda, Astellas and Dr. Reddy’s Laboratories, and as principal investigator in studies funded by Biohaven Pharmaceuticals, Theravance Biopharma and Biogen, and has received salary from Novartis. H.K. reports research funding from the National Institutes of Health (NIH R01, U54, U01), MJFF, MSA Coalition, Familial Dysautonomia Foundation, and the FDA; is an advisory board member for Lundbeck, Biogen, Biohaven, Theravance, PTC Therapeutics, ONO, Takeda, Vaxxinity and Elly Lilly; he is Editor-in-Chief of Clinical Autonomic Research and principal investigator in studies funded by Biogen. I.S. declares no competing interests.